Corbus Pharmaceuticals (CRBP) Expected to Release Earnings on Wednesday

Corbus Pharmaceuticals (NASDAQ:CRBP) will likely be issuing its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect the company to post earnings of ($1.2725) per share and revenue of $1.67 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 12:30 PM ET.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the consensus estimate of ($1.26) by ($0.55). On average, analysts expect Corbus Pharmaceuticals to post ($5.89) EPS for the current fiscal year and ($6.47) EPS for the next fiscal year.

Corbus Pharmaceuticals Stock Performance

CRBP stock opened at $3.87 on Wednesday. The business has a 50 day moving average price of $6.91 and a 200 day moving average price of $8.56. Corbus Pharmaceuticals has a fifty-two week low of $3.73 and a fifty-two week high of $12.88.

Insider Transactions at Corbus Pharmaceuticals

In other Corbus Pharmaceuticals news, CEO Yuval Cohen sold 17,000 shares of Corbus Pharmaceuticals stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $10.08, for a total transaction of $171,360.00. Following the transaction, the chief executive officer owned 157,316 shares of the company’s stock, valued at $1,585,745.28. The trade was a 9.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Nishant C. Saxena acquired 2,600 shares of Corbus Pharmaceuticals stock in a transaction on Tuesday, August 11th. The stock was purchased at an average price of $9.63 per share, with a total value of $25,038.00. Following the purchase, the insider owned 77,900 shares of the company’s stock, valued at $750,177. The trade was a 3.45% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders sold 456,000 shares of company stock valued at $2,050,500 in the last 90 days. Company insiders own 3.50% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on CRBP shares. HC Wainwright reissued a “buy” rating and set a $35.00 price objective on shares of Corbus Pharmaceuticals in a report on Monday, September 14th. Mizuho set a $33.00 target price on shares of Corbus Pharmaceuticals in a report on Thursday, August 13th. Wall Street Zen downgraded shares of Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Oppenheimer dropped their target price on shares of Corbus Pharmaceuticals from $52.00 to $48.00 and set an “outperform” rating on the stock in a research report on Friday, August 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research note on Thursday, October 15th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.57.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a biopharmaceutical company focused on developing medicines for serious diseases in oncology and immunology. The company’s research is centered on therapies designed to modulate immune-cell activity and target biological pathways involved in cancer and inflammatory disease.

Corbus’ oncology pipeline has included soquelitinib, formerly known as CPI-818, an oral, selective inhibitor of interleukin-2-inducible T-cell kinase (ITK) being evaluated for its potential to treat T-cell lymphomas and other cancers.